Santaris makes executive appointments
This article was originally published in Scrip
Denmark-based Santaris Pharma has expanded its executive team, appointing Dr Mark Wedel vice-president and chief medical officer and Stuart Mackey vice-president of strategy and chief business officer. Dr Wedel, who will be responsible for global clinical development programmes and therapeutic portfolio management, joins from Isis Pharmaceuticals, where he was senior vice-president of drug development and chief medical officer. Mr Mackey spent the last 10 years at Amgen, where he most recently served as managing director of Amgen Ventures. They will be responsible for driving global business development for Santaris's proprietary RNA-targeted Locked Nucleic Acid drug platform. Both executives will be located at the company's recently established US subsidiary in San Diego, California.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.